Patients
nausea or vomiting, bradycardia, hyperkalaemia, fever, malignancy, loss of taste or smell, chills, shortness of breath, sore throat, prolactin-secreting pituitary tumour, hypokalaemia, infections, muscle pain, fatigue, cough, nasal congestion, congestive heart failure, hypersensitivity, diarrhoea, heart disease, active SARS-CoV-2 infection, headache
SORE THROAT, HEART DISEASE, LIVER FAILURE, RENAL FAILURE, SEVERE OBESITY, INFECTIONS, PROLACTINOMA, GASTROINTESTINAL BLEEDING, ELECTROLYTE DISORDER, RESPIRATORY DISORDER, CONGESTIVE HEART FAILURE, ATRIAL FIBRILLATION, HYPOMAGNESAEMIA, HYPERSENSITIVITY, DISEASES
Eligible subjects were men or women aged 18 years or older, diagnosed with active SARS-CoV-2 infection confirmed by a positive rapid antigen detection test or a PCR test for viral RNA detection in the presence of compatible symptoms (fever, cough, shortness of breath or difficulty breathing, sore throat, body or muscle pain, fatigue, headache, chills, nasal congestion, loss of taste or smell, nausea or vomiting, and diarrhoea). It was required to have one or more symptoms within the last 72 h, with mild or moderate severity. Asymptomatic patients were eligible for the study if they had tested positive for SARS-CoV-2 within the previous 3 days. Exclusion criteria were patients living with a patient who had been enrolled in the present study, in order to avoid the exchange of medication between patients in the same household; patients with severe COVID-19; presence of diseases that may be affected or interfere with the results of the study (such as active infections other than SARS-CoV-2 requiring systemic therapy, uncontrolled respiratory disorder, prior ischemic heart disease, heart failure or atrial fibrillation, severe renal failure, active or treated malignancy, immunosuppression status, expected elective surgery within 30 days after screening for the study, severe obesity); concomitant treatment with drugs with known antiviral potential as remdesivir, lopinavir/ritonavir, chloroquine/hydroxychloroquine, tocilizumab, sarilumab, ruxolitinib, siltuximab, baricitinib, anakinra, interferon beta-1B, interferon alpha-2B, but not limited to this list; patients with domperidone use contraindications were excluded as patients with hypersensitivity or intolerance to domperidone or to any of the excipients, patients with prolactin-secreting pituitary tumour (prolactinoma), patients in whom stimulation of gastric motility may be dangerous, such as gastrointestinal bleeding, mechanical obstruction or perforation, patient with moderate-to-severe liver failure, with results in liver function tests, aspartate transaminase, alanine transaminase, alkaline phosphatase ≥5 times the upper limit of normal, patients with clinically significant abnormalities on the 12-lead electrocardiogram that may have been performed during the study screening period, specifically existing prolongation of cardiac conduction intervals, corrected QT interval, patient with underlying heart disease such as congestive heart failure or bradycardia, patient with significant electrolyte disorders such as hypokalaemia, hyperkalaemia, hypomagnesaemia, patient under treatment with drugs that prolong the QT interval, patient under treatment with potent CYP3A4 inhibitor drugs. Also, were excluded pregnant or breast-feeding women; patients unable to understand the informed consent; ineligibility as judged by the investigators; and participation in a clinical trial within the last 30 days. All the patients were informed about the study procedures and signed the informed consent form.